We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-23.86%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.2B
AUM Growth
-$1.2B
Cap. Flow
+$5.31M
Cap. Flow %
0.17%
Top 10 Hldgs %
52.42%
Holding
74
New
3
Increased
14
Reduced
34
Closed
4

Top Buys

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.1M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$31.7M
3
CNC icon
Centene
CNC
+$23.6M
4
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$18.2M
5
RAPT
RAPT Therapeutics
RAPT
+$17.7M

Top Sells

Rank Stock Value
1
ICUI icon
ICU Medical
ICUI
+$27.6M
2
GMAB icon
Genmab
GMAB
+$26.2M
3
UNH icon
UnitedHealth
UNH
+$24.6M
4
ZGNX
Zogenix, Inc.
ZGNX
+$16.2M
5
ELV icon
Elevance Health
ELV
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Consumer Staples 2.8%
3 Industrials 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LVTX
51
DELISTED
LAVA Therapeutics
LVTX
$12.4M 0.39%
2,816,196
– –
MDVL
52
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$10.8M 0.34%
221,502
– –
HOOK
53
DELISTED
HOOKIPA Pharma
HOOK
$10.6M 0.33%
463,665
+225,151
+94% +$4.04M
IVVD icon
54
Invivyd
IVVD
$180M
$8.76M 0.27%
1,920,960
– –
ANNX icon
55
Annexon
ANNX
$855M
$8.74M 0.27%
3,202,917
-26,000
-0.8% -$160K
TKNO icon
56
Alpha Teknova
TKNO
$266M
$7.84M 0.24%
567,800
-157,200
-22% -$2.47M
NGNE icon
57
Neurogene
NGNE
$696M
$6.51M 0.2%
173,272
-1,270
-0.7% -$74.1K
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.16M 0.19%
664,817
– –
IMTX icon
59
Immatics
IMTX
$1.24B
$5.79M 0.18%
725,000
-1,040,692
-59% -$9.48M
KLRS
60
Kalaris Therapeutics
KLRS
$88.7M
$5.56M 0.17%
35,799
– –
STXS icon
61
Stereotaxis
STXS
$129M
$5.55M 0.17%
1,487,495
-210,709
-12% -$995K
ACHL
62
DELISTED
Achilles Therapeutics
ACHL
$4.73M 0.15%
1,608,089
-480,000
-23% -$1.7M
TCRR
63
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.02M 0.09%
1,094,645
-251,413
-19% -$791K
XERS icon
64
Xeris Biopharma Holdings
XERS
$1.44B
$2.68M 0.08%
1,046,587
– –
BCEL
65
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.54M 0.08%
800,306
– –
SONX
66
DELISTED
Sonendo, Inc.
SONX
$2M 0.06%
498,131
– –
AYLA
67
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$1.79M 0.06%
449,731
-218,085
-33% -$1.13M
CABA icon
68
Cabaletta Bio
CABA
$439M
$1.41M 0.04%
696,377
– –
CTSO icon
69
Cytosorbents Corp
CTSO
$22.6M
$850K 0.03%
266,365
-450,879
-63% -$1.61M
EPZM
70
DELISTED
Epizyme, Inc
EPZM
$523K 0.02%
454,475
– –
GMAB icon
71
Genmab
GMAB
$17.7B
– –
-661,621
Closed -$26.2M
RCEL icon
72
Avita Medical
RCEL
$142M
– –
-672,411
Closed -$8.05M
NGM
73
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-582,805
Closed -$10.3M
ZGNX
74
DELISTED
Zogenix, Inc.
ZGNX
– –
-998,114
Closed -$16.2M
1 2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2022 Portfolio in Review

As of Q1 2022, Redmile Group held 74 positions worth $3.2B, down 27% from $4.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Redmile Group's Q1 2022 filing shows 3 new, 14 increased, 34 reduced and 4 closed positions. Its largest new stake was 1Life Healthcare: 3,404,835 shares worth $37.7M. The largest sale was ICU Medical, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Redmile Group's largest Q1 2022 buy was 1Life Healthcare: 3,404,835 shares worth $37.7M.
  • Redmile Group added most to Centene in Q1 2022, an estimated $23.6M increase.
  • Redmile Group's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $27.6M.
  • Redmile Group fully exited Genmab in Q1 2022, selling an estimated $26.2M.
  • Redmile Group's ten largest holdings make up 52% of its $3.2B portfolio in Q1 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q1 2022.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $3.2B.

Based on Redmile Group's 13F filing for Q1 2022, filed 16 May 2022.